Dragonfly Energy reported a net loss of $16.6 million for the nine months ended September 30, 2026, compared to a $24.9 million loss in the prior year period. Net sales decreased to $35.0 million from $45.6 million year-over-year, while the company's cash position significantly declined to $1.9 million as of September 30, 2026.
Syntec Optics reported net sales of $23.3 million for the nine months ended September 30, 2026, a 13.4% increase over the prior year. Despite the revenue growth, the company recorded a net loss of $395,046 for the period, though this was a significant improvement from the $1.45 million loss in 2025. The company's cash position strengthened substantially to $14.4 million following $23 million in gross proceeds from a common stock issuance.
As of September 30, 2026, the Canary XRP ETF held $368.8 million in XRP, representing a net asset value of $15.79 per share. For the nine months ended September 30, 2026, the Trust reported a net decrease in net assets from operations of $60.5 million, primarily driven by $50.2 million in unrealized depreciation and $9.2 million in realized losses on its crypto currency investments.
Eightco Holdings Inc. reported a significant shift in its business model towards a Digital Asset Treasury Strategy, with total assets increasing to $446.3 million as of September 30, 2026, primarily driven by $205.4 million in digital assets and $82.6 million in stablecoins. However, the company experienced a sharp decline in revenues to $9.7 million for the nine months ended September 30, 2026, compared to $22.8 million in the prior year, resulting in an operating loss of $25.9 million.
Apollo Asset Backed Credit Company LLC reported total net assets of approximately $1.98 billion as of September 30, 2026, across its Series I and Series II interests. The company, an emerging growth company, saw its total assets grow to $2.52 billion from $1.89 billion at the end of 2025, driven primarily by an increase in investments at fair value.
Tempest Therapeutics reported third quarter 2026 financial results and provided a business update on its in vivo CAR-T pipeline, including the lead candidate TPST-4903. During the quarter, the company exercised its option for an exclusive license to Senlang's CD7-targeted platform and secured access to capital through a $50 million equity line of credit and a $2.5 million private placement.
“The third quarter marked a period of meaningful progress in the advancement of two next-generation in vivo CAR-T platforms with the potential to transform treatment across multiple diseases.”
Matt Angel, Ph.D., president and chief executive officer of Tempest
“We made important strides in expanding our pipeline and strengthening our position in the rapidly evolving in vivo CAR-T landscape through our strategic collaboration with Senlang by obtaining exclusive license rights to our clinical-stage BCMA/GPRC5D in vivo CAR-T candidate TPST-4903, while securing access to additional capital to support our development priorities.”
Matt Angel, Ph.D., president and chief executive officer of Tempest
BeyondSpring reported Q3 2026 financial results and highlighted that the FDA granted Fast Track designation for Plinabulin in combination with docetaxel for certain NSCLC patients. The company also completed a strategic transaction with Biolin to fund approximately half of the enrollment for the Phase 3 DUBLIN-4 trial.
Term
Q3 2026
“The FDA’s Fast Track designation underscores the significant unmet need for new treatment options for NSCLC patients without AGA and progressing after immune checkpoint inhibitor therapy, where docetaxel is still the standard of care.”
Min Qiu, Chief Executive Officer of BeyondSpring
“With an FDA-aligned Phase 3 design and a strategic transaction with Biolin to support approximately half of DUBLIN-4’s planned 442-patient enrollment, generating quality data from China, we remain focused on advancing the study toward its prespecified interim analysis at 221 progression-free survival events.”
Awaysis Capital, Inc. reported a net loss of $602,539 for the three months ended September 30, 2026, compared to a net loss of $651,548 in the prior year period. Revenue increased to $164,671 from $95,198, while the company continued to focus on its vacation rental and real estate development activities in Belize.
BCP Investment Corporation reported Q3 2026 financial results with total investment income of $13.9 million and net investment income of $4.6 million ($0.37 per share). The company also announced a definitive merger agreement to acquire Investcorp Credit Management BDC, Inc. (ICMB) at 90% of its closing NAV. Additionally, BCIC declared monthly base distributions of $0.09 per share for the first quarter of 2027.
FORUM MARKETS Inc. reported a net income of $7.85 million for the quarter ended September 30, 2026, a significant recovery from a $216.7 million loss in the prior year. The company transitioned its revenue model toward aircraft engine rentals while managing a substantial accumulated deficit of $673.3 million.
Tempest Therapeutics filed its Q3 2026 10-Q reporting 19,995,358 shares of common stock outstanding as of November 13, 2026. The company is focused on advancing its clinical-stage programs, including TPST-4003 and TPST-2003, while addressing substantial risks regarding its ability to continue as a going concern and maintain Nasdaq listing compliance.
RTB Digital, Inc. reported a significant revenue increase to $6.29 million for the nine months ended September 30, 2026, compared to $1.44 million in the prior year, driven by expansion and acquisitions. However, the company incurred a net loss of $19.44 million during this period, primarily due to a sharp rise in general and administrative expenses and losses on the sale of crypto assets.
CISO Global reported total revenue of $17.6 million for the nine months ended September 30, 2026, a decrease from $20.3 million in the prior year period. The company reported a net loss of $6.3 million for the first nine months of 2026 and expressed substantial doubt about its ability to continue as a going concern.
GBank Financial Holdings Inc. reported on its financial condition for the quarter ended September 30, 2026, highlighting risks related to credit quality, inflationary pressures, and cybersecurity. As of November 13, 2026, the company had 14,571,526 shares of common stock outstanding and is classified as an emerging growth company.
Canary HBAR ETF reported net assets of $87.5 million as of September 30, 2026, a significant increase from $50.6 million at the end of 2025, driven by $30.4 million in net capital share transactions and $6.5 million in net increase from operations. The Trust's investment in Hedera (HBAR) grew to over 806 million units, though it recorded a net investment loss of $383,993 for the nine-month period due to sponsor fees.
Silvia, Inc. reported a net loss of $49.95 million for the nine months ended September 30, 2026, primarily driven by $17.65 million in unrealized losses on digital assets and $11.01 million in stock-based compensation. Despite the year-to-date loss, the company achieved a net income of $122.85 million in the third quarter of 2026 due to a significant $137.18 million unrealized gain on digital assets.
Talon Capital Corp. reported net income of $5,279,431 for the nine months ended September 30, 2026, primarily driven by $7,057,830 in interest earned on cash held in the Trust Account. The company remains a shell company with $258,717,921 in Class A ordinary shares subject to possible redemption and a total shareholders' deficit of $8,576,577.
As of September 30, 2026, the Canary Staked SUI ETF held net assets of $33,887,152, primarily consisting of SUI cryptocurrency valued at $33,936,747. For the period from its inception on February 17, 2026, through September 30, 2026, the Trust reported a net increase in net assets from operations of $5,766,462, driven largely by $5,780,708 in unrealized appreciation on its SUI holdings.
Cingulate Inc. reported a net loss of $22.9 million for the nine months ended September 30, 2026, as it continues to develop its ADHD drug candidates CTx-1301 and CTx-1302. Despite receiving a Complete Response Letter from the FDA for CTx-1301 in June 2026, the company strengthened its liquidity position to $23.2 million in cash through significant financing activities, including at-the-market offerings and private placements.
For the nine months ended September 30, 2026, the Trust incurred $5,864 in Sponsor Fees, with $3,202 waived under a fee waiver that expired on June 30, 2026. The Trust saw net share creation activity of 90,000 shares valued at approximately $2.07 million during the first nine months of 2026.
Canary Litecoin ETF reported net assets of $14.19 million as of September 30, 2026, a significant increase from $6.96 million at the end of 2025, driven primarily by $8.30 million in net capital share transactions. The Trust experienced a net decrease in net assets from operations of $1.07 million for the nine months ended September 30, 2026, as realized losses on Litecoin holdings outweighed unrealized appreciation.
For the quarter ended September 30, 2026, the Trust's NAV per share increased from $37.86 to $51.29, driven by a total return of 35.99%. The Trust held 1,023,491 HYPE tokens valued at approximately $90.8 million, despite a net redemption of 110,000 shares during the period.
CSB Financial Inc. completed its mutual-to-stock conversion in 2026, raising $12.1 million in net proceeds and issuing 1,402,935 shares. For the nine months ended September 30, 2026, net income was $136,612, down from $325,585 in the prior year, primarily due to a $375,000 one-time charitable contribution related to the conversion.
CoJax Oil & Gas Corp reported a net income of $2,895 for the quarter ended September 30, 2026, a significant improvement from a net loss of $157,705 in the prior year period. Despite achieving profitability in the last two quarters, management expressed substantial doubt about the company's ability to continue as a going concern due to insufficient profits to support business expansion.
Enhanced Group Inc. is an emerging growth company focused on enhancement-based athletic competition and the Live Enhanced platform. The filing highlights significant risks including a limited operating history, minimal revenues, and a need for additional capital to continue as a going concern following its recent business combination.
Cingulate reported Q3 2026 financial results, highlighting a cash position of $23.2 million and progress on its CTx-1301 NDA resubmission. The company has substantially completed manufacturing work to address FDA CMC requests and expects to resubmit the NDA between December 2026 and January 2027. Additionally, the company added Maxim Group LLC as a sales agent to its existing $100 million ATM equity offering program.
Term
Q3 2026
“With the manufacturing work substantially complete, we are now finalizing the data and documentation needed to resubmit the NDA for CTx-1301, and we expect to do so by January 2027, potentially sooner.”
Shane J. Schaffer, Chairman and CEO
“Importantly, the FDA’s Complete Response Letter did not raise any concerns about the clinical safety or efficacy of CTx-1301. We thank our shareholders for their patience and continued support as we work to bring this treatment to patients with ADHD.”
Amaze Holdings, Inc. reported a significant net loss of $32.3 million for the nine months ended September 30, 2026, primarily driven by a $17.7 million impairment of intangible assets. Revenues declined sharply to $0.47 million in the third quarter compared to $1.25 million in the prior year period, while the company's stockholders' equity shifted from a surplus of $9.8 million to a deficit of $8.2 million.
Edgewell Personal Care Co. is focused on its 'Sustainable Care' strategy, targeting reductions in petroleum-based plastics, greenhouse gas emissions, and waste diversion. The company reported approximately 6,500 employees as of September 30, 2026, and continues to manage significant regulatory compliance obligations under the FDA, CPSC, TSCA, and REACH frameworks.
Pasithea Therapeutics Corp. reported a net loss of $14.7 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses to $11.1 million. The company maintained a cash position of $41.2 million as of the end of the period, down from $55.2 million at the start of the year.
For the nine months ended September 30, 2026, Health In Tech, Inc. reported total revenues of $23.4 million, a decrease from $25.8 million in the prior year period. The company experienced a significant shift in its financial position, moving from a retained earnings balance of $5.2 million at the end of 2025 to an accumulated deficit of $5.9 million as of September 30, 2026.